Abstract
Background The gut-lung axis is generally recognized, but there are few large studies of the gut microbiome and incident respiratory disease in adults.
Objectives3 To investigate the associations between gut microbiome and respiratory disease and to construct predictive models from baseline gut microbiome profiles for incident asthma or chronic obstructive pulmonary disease (COPD).
Methods Shallow metagenomic sequencing was performed for stool samples from a prospective, population-based cohort (FINRISK02; N=7,115 adults) with linked national administrative health register derived classifications for incident asthma and COPD up to 15 years after baseline. Generalised linear models and Cox regressions were utilised to assess associations of microbial taxa and diversity with disease occurrence. Predictive models were constructed using machine learning with extreme gradient boosting. Models considered taxa abundances individually and in combination with other risk factors, including sex, age, body mass index and smoking status.
Results A total of 695 and 392 significant microbial associations at different taxonomic levels were found with incident asthma and COPD, respectively. Gradient boosting decision trees of baseline gut microbiome predicted incident asthma and COPD with mean area under the curves of 0.608 and 0.780, respectively. For both incident asthma and COPD, the baseline gut microbiome had C-indices of 0.623 for asthma and 0.817 for COPD, which were more predictive than other conventional risk factors. The integration of gut microbiome and conventional risk factors further improved prediction capacities. Subgroup analyses indicated gut microbiome was significantly associated with incident COPD in both current smokers and non-smokers, as well as in individuals who reported never smoking.
Conclusions The gut microbiome is a significant risk factor for incident asthma and incident COPD and is largely independent of conventional risk factors.
Competing Interest Statement
VS has received honoraria from Sanofi for consulting. He also has ongoing research collaboration with Bayer Ltd. (All outside this study).
Funding Statement
VS was supported by the Finnish Foundation for Cardiovascular Research and by Juho Vainio Foundation. MI was supported by the Munz Chair of Cardiovascular Prediction and Prevention. ASH was supported by the Academy of Finland, grant no. 321356. LL was supported by Academy of Finland (295741, 328791). TN was supported by the Emil Aaltonen Foundation, the Finnish Foundation for Cardiovascular Research and the Academy of Finland (grant no. 321351). This study was supported by the Victorian Government Operational Infrastructure Support (OIS) program and by core funding from the British Heart Foundation (RG/13/13/30194; RG/18/13/33946) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*]. *The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. *The views expressed are those of the authors and not necessarily those of the NHS or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Coordinating Ethics Committee of the Helsinki University Hospital District approved the study protocol for FINRISK 2002 (Ref. 558/E3/2001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The FINRISK data for this study are available with a written application to the THL Biobank as instructed on the website: https://thl.fi/en/web/thl-biobank/for-researchers.
